From mitochondrial signal to discovery decision: a reserve–demand framework for translational Risk assessment

INTRODUCTION: Mitochondrial safety assessment is used in drug discovery, supported by bioenergetic profiling, mechanistic assays, human-relevant cellular systems, and multidimensional data. These advances have improved detection of mitochondrial perturbation but have not solved the harder problem: how such signals should be interpreted and translated into discovery decisions. AREAS COVERED: This perspective proposes a qualitative decision-centered framework for interpreting mitochondrial findings. This framework is anchored in reserve - demand biology, which explains why mitochondrial perturbations become consequential when drug-induced reductions in bioenergetic capacity intersect with tissue-specific demand, exposure, duration, and stress context. Furthermore, the authors describe a qualitative Translational Risk Profile organized around mechanistic severity, exposure relevance, temporal progression, and translational concordance. This profile is paired with a Decision Taxonomy: Stop, Optimize, Monitor, or Acceptable Risk. Examples illustrate how mitochondrial evidence patterns can support different discovery actions. EXPERT OPINION: The major limitation in mitochondrial safety assessment is no longer signal detection, but decision-oriented interpretation. Future progress will depend on integrating mechanism, exposure, duration, biomarkers, human-relevant models and quantitative or computational evidence into explicit decision frameworks. Mitochondrial findings should not be treated as binary hazards. They should be interpreted as context-dependent evidence that can guide chemistry, candidate selection, monitoring strategy, and translational risk management.

Authors

Institutions

Publication Details

Journal
Expert Opinion on Drug Discovery
Published
2026-06-30
DOI
https://doi.org/10.1080/17460441.2026.2697796
Primary Topic
Mitochondrial Function and Pathology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From mitochondrial signal to discovery decision: a reserve–demand framework for translational Risk assessment

George W. Rogers, Yvonne Will
Expert Opinion on Drug Discovery
Mitochondrial Function and Pathology
article

From mitochondrial signal to discovery decision: a reserve–demand framework for translational Risk assessment

George W. Rogers, Yvonne Will
article en

Abstract

INTRODUCTION: Mitochondrial safety assessment is used in drug discovery, supported by bioenergetic profiling, mechanistic assays, human-relevant cellular systems, and multidimensional data. These advances have improved detection of mitochondrial perturbation but have not solved the harder problem: how such signals should be interpreted and translated into discovery decisions. AREAS COVERED: This perspective proposes a qualitative decision-centered framework for interpreting mitochondrial findings. This framework is anchored in reserve - demand biology, which explains why mitochondrial perturbations become consequential when drug-induced reductions in bioenergetic capacity intersect with tissue-specific demand, exposure, duration, and stress context. Furthermore, the authors describe a qualitative Translational Risk Profile organized around mechanistic severity, exposure relevance, temporal progression, and translational concordance. This profile is paired with a Decision Taxonomy: Stop, Optimize, Monitor, or Acceptable Risk. Examples illustrate how mitochondrial evidence patterns can support different discovery actions. EXPERT OPINION: The major limitation in mitochondrial safety assessment is no longer signal detection, but decision-oriented interpretation. Future progress will depend on integrating mechanism, exposure, duration, biomarkers, human-relevant models and quantitative or computational evidence into explicit decision frameworks. Mitochondrial findings should not be treated as binary hazards. They should be interpreted as context-dependent evidence that can guide chemistry, candidate selection, monitoring strategy, and translational risk management.

Expert Opinion on Drug Discovery
Department of Biomedicine Basel (CH), Clinical Research Consultants (United States) (US)
Openalex Percentile: Top 11%
Mitochondrial Function and Pathology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.